Featured Research

from universities, journals, and other organizations

Newest cancer therapies multi-task to eliminate tumors

Date:
September 18, 2011
Source:
Georgia Health Sciences University
Summary:
Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, researchers report.

Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report.

These immunotherapies, such as CTLA4, strengthen the immune system's attack on cancer by keeping apart two proteins that prevent key immune cells called T cells from activating.

Research featured on the cover of the Journal of Immunology suggests that these therapies also keep tumors from benefiting from IDO, an enzyme used by fetuses and tumors alike to suppress the immune response.

"This is an alternative way of avoiding the immune system brakes," said Dr. Andrew Mellor, Director of the GHSU Immunotherapy Center and the study's corresponding author. "These findings give us better insight into how cancer immunotherapy works so in the future we can better minimize the side effects and maximize the effect we want which is anti-tumor."

Mellor and Dr. David Munn, who leads the Cancer Immunotherapy Program in the GHSU Cancer Center and co-authored the study, led a research team that in 1998 identified IDO's role in preventing a mother's immune system from rejecting a fetus. They subsequently learned that tumors pirate the mechanism. The university has patented technologies to inhibit IDO, which are currently in clinical trials funded by the National Cancer Institute and corporate partners. "Tumors are really good at turning on IDO and after the cancer is found it becomes important to turn it off," Mellor said.

The study also provides new insight into cancer treatment vaccines that have worked well in the laboratory but are less successful in patients, Mellor said.

It suggests that the quantity of bacterial mimics, which get the attention of the immune system, is pivotal. Mellor and his colleagues showed in 2005 that the bacterial mimic CpG-ODNs can actually activate IDO. The new study confirmed that a lower dose avoided stimulating IDO while higher doses turned it on.

It also may help explain a common cancer vaccine side effect: the immune system's attack on healthy as well as cancerous tissue.

IDO, or indoleomine 2,3-dioxyegenase, locally suppresses immune system action by degrading tryptophan, an amino acid essential to survival of T-cells, orchestrators of immune response. Along with tumors, infectious agents, such as HIV, may use this mechanism to escape the immune system. In addition to pursuing the cancer treatment potential of IDO inhibitors, GHSU researchers have been looking at how invoking IDO can protect transplanted organs or treat autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, respectively.

Collaborators include Dr. Babak Baban, Assistant Professor of Oral Biology in the GHSU College of Dental Medicine, who is first author on the study, as well as investigators at Harvard University and the University of Minnesota. Mellor is the Bradley-Turner Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. The research was funded by the National Institutes of Health.


Story Source:

The above story is based on materials provided by Georgia Health Sciences University. Note: Materials may be edited for content and length.


Journal Reference:

  1. B. Baban, P. R. Chandler, B. A. Johnson, L. Huang, M. Li, M. L. Sharpe, L. M. Francisco, A. H. Sharpe, B. R. Blazar, D. H. Munn, A. L. Mellor. Physiologic Control of IDO Competence in Splenic Dendritic Cells. The Journal of Immunology, 2011; 187 (5): 2329 DOI: 10.4049/jimmunol.1100276

Cite This Page:

Georgia Health Sciences University. "Newest cancer therapies multi-task to eliminate tumors." ScienceDaily. ScienceDaily, 18 September 2011. <www.sciencedaily.com/releases/2011/09/110916092940.htm>.
Georgia Health Sciences University. (2011, September 18). Newest cancer therapies multi-task to eliminate tumors. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/09/110916092940.htm
Georgia Health Sciences University. "Newest cancer therapies multi-task to eliminate tumors." ScienceDaily. www.sciencedaily.com/releases/2011/09/110916092940.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins